Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing psychedelics to therapeutics(TM), has been granted a Schedule I manufacturing license from the U.S. Drug Enforcement Agency (“DEA”). Granted for Cybin’s research lab located in the Boston area, the license is required for investigators who plan to study, produce, analyze or otherwise work with Schedule I controlled substances. According to the announcement, the company is working to become a hub for innovation and drug discovery. Cybin has relied on in-house capabilities as well as globally licensed research organizations in the United States, Canada and the United Kingdom for most of its research and development (“R&D”). With the DEA license, the company anticipates expanding R&D efforts involving Schedule I compounds. The company also named Leah Gibson as its new vice president of investor relations. A life sciences investor relations leader, Gibson has more than 18 years of experience in corporate and shareholder communications as well as business strategy development. “We are pleased with the progression of our clinical and regulatory efforts since the company’s formation,” said Cybin’s CEO Doug Drysdale in the press release. “This new license further positions the company as a truly integrated biopharmaceutical company that can continue to work towards progressing Psychedelics to Therapeutics(TM).”
To view the full press release, visit https://ibn.fm/aCxxF
About Cybin Inc.
Cybin is a leading ethical biopharmaceutical company, working with a network of world-class partners and internationally recognized scientists on a mission to create safe and effective therapeutics for patients to address a multitude of mental health issues. Headquartered in Canada and founded in 2019, Cybin is operational in the United States, United Kingdom and Ireland. The company is focused on progressing Psychedelics to Therapeutics by engineering proprietary drug-discovery platforms, innovative drug-delivery systems, novel formulation approaches and treatment regimens for mental health disorders. For more information, visit the company’s website at www.Cybin.com.
NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
Editor@PsychedelicWire.com
PsychedelicNewsWire is part of the InvestorBrandNetwork.